Idaho Could Become the 42nd Medical Cannabis State This November: A Breakdown of the Idaho Medical Cannabis Act

Idaho voters are likely to decide this November whether to make the state the 42nd in the nation with a comprehensive medical cannabis program, after supporters of the Idaho Medical Cannabis Act submitted more than 150,000 signatures, more than double the 70,725 valid signatures required to qualify. The signatures still must be verified, but the high number puts the measure in a strong position to appear on the November 2026 ballot.

If approved, the Idaho Medical Cannabis Act would authorize the growth, possession, distribution, transportation, processing, sale and use of medical cannabis for patients diagnosed with a “substantial health condition.” The proposal would create a state-regulated system overseen primarily by the Idaho State Board of Pharmacy and the Idaho Department of Health and Welfare.

Patients would be able to apply for a medical cannabis card beginning July 1, 2027. To qualify, an applicant would need a diagnosis from a qualified practitioner, a medical record showing that diagnosis within two years of applying, a government-issued identification card, and payment of an application fee set by the Department of Health and Welfare. The fee could not exceed the cost of administering the card program. Cards would be valid for up to 12 months and could be renewed annually.

Qualifying conditions would include cancer, AIDS or HIV, Alzheimer’s disease, ALS, anxiety, autism, cachexia, Crohn’s disease, irritable bowel syndrome, ulcerative colitis, epilepsy, debilitating seizures, Tourette syndrome, glaucoma, macular degeneration, insomnia, multiple sclerosis, debilitating muscle spasms, certain forms of nausea, acute pain lasting longer than two weeks, chronic and persistent pain not adequately managed by conventional treatments other than opioids or opiates, PTSD, terminal illness, hospice care, palliative care, comfort care, and rare diseases affecting fewer than 200,000 people in the United States. The Board of Pharmacy would also be allowed to add conditions through rulemaking.

The initiative would allow smokeable cannabis, inhalable cannabis and certain ingestible products. Ingestible medical cannabis would be limited to tablets, chewables, droplets or pills containing up to 10 milligrams of THC per unit. Patients would be capped at either 113 grams of smokeable cannabis or 20 grams of total composite THC in inhalable or qualifying ingestible products per month, and the measure says cardholders could not combine those limits in the same month.

The measure would also allow patients to designate one or more licensed caregivers to help obtain and handle medical cannabis. Cardholders would be required to carry both their medical cannabis card and government-issued identification when purchasing, possessing or using medical cannabis under the program.

On the business side, the initiative would create medical cannabis production licenses allowing licensed companies to grow, handle, process, manufacture, test, transport, distribute, deliver and sell medical cannabis to cardholders. Applicants would need to show they have held a consecutive Idaho hemp license in good standing since 2022, submit an operating plan, provide letters of recommendation from the local community, disclose individuals with at least a 5% financial or voting interest, and identify a licensed pharmacist who would provide oversight for dispensing, storage, distribution and sales.

The program would be limited. The Board of Pharmacy could issue no more than three initial medical cannabis production licenses. Additional licenses could be added only after Idaho’s population grows by 650,000 residents from 2027, with no more than six total licenses statewide. Each license holder would be allowed no more than two cultivation and production facilities and up to six retail locations.

Licensed production facilities would need to be located in agricultural zones and at least a half-mile from areas zoned primarily residential when the act takes effect. Sales could occur through retail locations, online orders with in-person delivery, pickup at retail locations or fulfillment centers, and in-person delivery.

The operating plan required for licensees would need to cover facility details, fulfillment and distribution centers, retail facilities, employee training, security, inventory control, storage protocols, cultivation practices, pesticide and fertilizer use, expected yield, extraction methods, processing equipment, sanitation procedures and testing practices. Applicants and certain owners or managers would also undergo fingerprint-based background checks through Idaho State Police and the FBI.

The measure would require pharmacist oversight for dispensing, storing, distributing and selling medical cannabis. Products would also need warning labels stating that cannabis has intoxicating effects, may be addictive, should be kept out of reach of children and is for medical use only. Additional warnings about overconsumption and other information deemed appropriate by the board could also be required.

The act includes several patient and provider protections. Practitioners, pharmacists, patients and others acting within the program would not be subject to arrest, prosecution, civil penalties or licensing discipline under state law for conduct allowed by the initiative. Landlords, schools and colleges could not refuse to lease to or enroll someone solely for activity allowed under the act, with exceptions tied to federal law or federal funding.

Employers could not discriminate in hiring, firing or other terms of employment solely because of a person’s lawful medical cannabis activity, though employers would not be required to allow cannabis use at work or allow an employee to work while impaired. The measure also states that a cardholder would not be considered under the influence solely because of cannabis metabolites or components that appear in a concentration too low to cause impairment.

The proposal would also protect custody and visitation rights, and it says medical cannabis use could not be treated as illicit substance use for purposes of denying medical care, including organ transplants. State and local governments would be directed, where possible, to treat authorized medical cannabis use similarly to the use of prescribed opioids or opiates, unless doing so would jeopardize federal funding.

The initiative would not allow public use. Smoking, vaping or otherwise inhaling medical cannabis in a public area would remain unlawful, as would impaired driving and giving or selling medical cannabis to someone not authorized under the act. Violations could be misdemeanors punishable by a $1,000 fine, and a cardholder who sells or gives cannabis to another person could have their card permanently revoked.

The act would create a Qualified Patient Enterprise Fund, funded by fees, administrative fines, legislative appropriations and interest. Money in the fund would be used to carry out the Board of Pharmacy’s responsibilities and to fund peer-reviewed studies on the medical use of cannabis. The measure would not require insurers or employers to pay for or reimburse patients for medical cannabis.

Medical cannabis sales would be subject to Idaho’s sales tax, according to the official fiscal analysis. The state estimates the initiative would generate between $600,000 and $8 million in annual revenue from sales taxes in the first full year of implementation, in addition to revenue from patient card fees and production license fees. Estimated ongoing annual costs are listed at $1.1 million, with start-up and ongoing costs spread across the Board of Pharmacy, Department of Health and Welfare and Idaho State Police.

The proposal comes as Idaho lawmakers have also placed HJR 4 on the 2026 ballot, a constitutional amendment that would give only the Legislature the authority to legalize marijuana, narcotics or other psychoactive substances and remove citizens’ ability to use initiated statutes to legalize or decriminalize those substances in the future. That means the Idaho Medical Cannabis Act could represent one of the final opportunities for voters to enact marijuana reform directly through the initiative process.